NorthSea Therapeutics appoints Morris J. Birnbaum to the Board

Former Pfizer Internal Medicine CSO joins the Boardas an independent board member   Amsterdam, The Netherlands, 21 December 2022 – NorthSea Therapeutics B.V. (‘NST’), a  biotech company developing novel and innovative strategies for the treatment of...

“We believe icosabutate has the potential to impact the lives of millions of NASH patients globally”
Rob de Ree

Chief Executive Officer, NorthSea Therapeutics

More information:

+31 (0) 35 760 65 05